Sweden Hereditary Angioedema Therapeutics Market Size & Outlook
Sweden hereditary angioedema therapeutics market, 2018-2030 (US$M)
Related Markets
Sweden hereditary angioedema therapeutics market highlights
- The Sweden hereditary angioedema therapeutics market generated a revenue of USD 31.2 million in 2023 and is expected to reach USD 77.3 million by 2030.
- The Sweden market is expected to grow at a CAGR of 13.8% from 2024 to 2030.
- In terms of segment, kallikrein inhibitor was the largest revenue generating treatment in 2023.
- Kallikrein inhibitor is the most lucrative treatment segment registering the fastest growth during the forecast period.
Hereditary angioedema therapeutics market data book summary
| Market revenue in 2023 | USD 31.2 million |
| Market revenue in 2030 | USD 77.3 million |
| Growth rate | 13.8% (CAGR from 2023 to 2030) |
| Largest segment | Kallikrein inhibitor |
| Fastest growing segment | Kallikrein inhibitor |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others Treatment |
| Key market players worldwide | BioCryst Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, CSL Ltd, Adverum Biotechnologies Inc, KalVista Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, Pharming Group, Attune Pharmaceuticals |
Other key industry trends
- In terms of revenue, Sweden accounted for 1.1% of the global hereditary angioedema therapeutics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany hereditary angioedema therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 276.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Hereditary Angioedema Therapeutics Market Scope
Hereditary Angioedema Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Sweden hereditary angioedema therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary angioedema therapeutics market will help companies and investors design strategic landscapes.
Kallikrein inhibitor was the largest segment with a revenue share of 44.87% in 2023. Horizon Databook has segmented the Sweden hereditary angioedema therapeutics market based on c1-esterase inhibitor, bradykinin b2 receptor antagonist, kallikrein inhibitor, others treatment covering the revenue growth of each sub-segment from 2018 to 2030.
In Sweden, there is an increasing incidence of mortalities caused by the condition, which creates a significant demand for therapeutics in the country. However, key players in the market are continuously focusing on developing novel therapeutics to address the condition in the country.
For instance, in March 2022, Newbury Pharmaceuticals announced the launch of icatibant injection in Sweden used for the treatment of acute attacks of HAE. Continuous developments by companies operating in the market are contributing to the market growth.
Reasons to subscribe to Sweden hereditary angioedema therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Sweden hereditary angioedema therapeutics market databook
-
Our clientele includes a mix of hereditary angioedema therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden hereditary angioedema therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Sweden hereditary angioedema therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Sweden hereditary angioedema hae therapeutics market size, by treatment, 2018-2030 (US$M)
Sweden Hereditary Angioedema Therapeutics Market Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
